Abstract: Embodiments of the disclosure pertain to the field of HLA-G molecules and their therapeutic use. The disclosure pertains to new HLA-G isoforms, that is to say new RNA transcripts and proteins deriving from the HLA-G gene, pharmaceutical composition comprising thereof, as well as primers specific of these transcripts and antibodies specific of these proteins. The disclosure further pertains to the diagnostic or therapeutic use of these molecules.

Abstract: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

Abstract: The present disclosure relates to a method for transforming wood residues into an edible food product for a mammal, consisting of a sequence of fungal fermentations which make it possible to render ligneous resources edible; the invention also relates to the food product obtained by this method, and to the use thereof.

Abstract: Embodiments of the disclosure pertain to the field of HLA-G molecules and their therapeutic use. The disclosure pertains to new HLA-G isoforms, that is to say new RNA transcripts and proteins deriving from the HLA-G gene, pharmaceutical composition comprising thereof, as well as primers specific of these transcripts and antibodies specific of these proteins. The disclosure further pertains to the diagnostic or therapeutic use of these molecules.

Abstract: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

Abstract: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

Abstract: The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid. The invention first relates to a product containing at least one connexin-blocking agent and a psychotropic drug as combination products for use simultaneously, separately, or spread over time in patients suffering from psychiatric and/or neurodegenerative disorders. The connexin-blocking agent is advantageously selected from the group comprising meclofenamic acid, 18-?-glycyrrhetinic acid, carbenoxolone, mefloquine, and 2-APB, and preferably consists of meclofenamic acid.

Abstract: The invention relates to a method for diagnosing a transmissible spongiform subacute encephalopathy (TSSE) caused by an unconventional transmissible agent (UTA) or prion. The method involves treating a sample suspected of containing a prion with proteinase K for a time and under conditions that completely degrade normal prion protein (Prp-sen), but which only partially digest abnormal prion protein (PrP-res) so that all or some of the octapeptide motif repeats comprising P(H/Q)GGG(-/T)WGQ (SEQ ID NO: 1) in the abnormal prion protein (Prp-res) are retained.

Abstract: The invention relates to a method for diagnosing a transmissible spongiform subacute encephalopathy (TSSE) caused by an unconventional transmissible agent (UTA) or prion. The method involves treating a sample suspected of containing a prion with proteinase K for a time and under conditions that completely degrade normal prion protein (Prp-sen), but which only partially digest abnormal prion protein (PrP-res) so that all or some of the octapeptide motif repeats comprising P(H/Q)GGG(-/T)WGQ (SEQ ID NO: 1) in the abnormal prion protein (Prp-res) are retained.

Abstract: The invention relates to a method for diagnosing a transmissible spongiform subacute encephalopathy (TSSE) caused by an unconventional transmissible agent (UTA) or prion. The method involves treating a sample suspected of containing a prion with proteinase K for a time and under conditions that completely degrade normal prion protein (Prp-sen), but which only partially digest abnormal prion protein (PrP-res) so that all or some of the octapeptide motif repeats comprising P(H/Q)GGG(?/T)WGQ (SEQ ID NO: 1) in the abnormal prion protein (Prp-res) are retained.

Abstract: The invention concerns a method for screening substances capable of having therapeutic action in the treatment of transmissible subacute spongiform encephalopathy (TSSE) or prion diseases comprising a step of isolating the PrPres, from the spleen, methods for isolating the PrPres, particularly adapted to said screening method and their applications, in particular for detecting PrPres.

Abstract: The invention relates to a device for collecting a soft biological sample and to a method for using the same. The device comprises a hollow cylindrical body (10) with two openings (10A, 10B), one at each end, wherein a piston (12) with a rod (14) is inserted via a first end and the piston-and-rod assembly can be displaced back and forth inside the hollow cylindrically (10), the opening in the second end (10B) of the hollow cylindrical body (10) has a slicing edge (10B) and this second end carries a cutting wire arranged across its opening.

Abstract: The invention concerns a method for purifying PrPres from a biological sample to be used for qualitative and/or quantitative determination of the PrPres in said sample. The method essentially consists in: (1) incubating, during 30 seconds to 2 hours, at a temperature less than 80° C.

Abstract: The invention relates to a device for taking a soft biological sample and a method for the implementation thereof. The device comprises a hollow cylindrical body (10) with two openings (10A, 10B), one at each end, wherein a piston (12) with a rod (14) is inserted via a first end and the piston and rod unit can be displaced back and forth inside the hollow cylindrical body (10). The opening of the second end (10B) of the hollow cylindrical body (10) has a cutting edge (10B). Said second end comprises a cutting wire which is disposed across the opening.